ArticleCellular and molecular gastroenterology and hepatology2022
Gut-innervating TRPV1+ Neurons Drive Chronic Visceral Pain via Microglial P2Y12 Receptor.
Article in Cellular and molecular gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Mechanisms of chronic abdominal pain in inflammatory bowel disease and implications for treatment.Nature reviews. Gastroenterology & hepatology · 2026Review
- Autonomic nervous system dysfunction in irritable bowel syndrome: pathophysiology and therapeutic implications.Frontiers in neuroscience · 2026Review
- Neuroimmune regulation of visceral pain: roles of microglia, purinergic signaling, and neuroinflammation.Frontiers in immunology · 2026Review
- Chronic gut inflammation differentially modulates mitochondrial and antioxidant transcriptional programs in limbic brain structures.Scientific reports · 2025Article
- Neuro-immune cross-talk in cancer.Nature reviews. Cancer · 2025Review
- Review
- Electroacupuncture alleviates capsaicin-induced rectal visceral pain in rats via inhibiting TRPV1 expression by blocking the P2X4R-activated p38 pathway.Purinergic signalling · 2025Article
- Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Decoding Abdominal Pain in Constipation-predominant Irritable Bowel Syndrome and Functional Constipation: Mechanisms and Managements.Current gastroenterology reports · 2025Review
- Spinal sensory innervation of the intestine.Current opinion in neurobiology · 2025Review
- Neuro-immune cell interactions in the regulation of intestinal immune homeostasis.Current opinion in gastroenterology · 2025Review
- Central obesity rather than BMI is associated with chronic pain: A cross-sectional analysis of NHANES.PloS one · 2025Article
- Acupuncture and moxibustion in irritable bowel syndrome: a mechanistic exploration from heart rate variability to cardiac metabolism.Frontiers in neurology · 2025Article
- Abdominal Pain in Inflammatory Bowel Disease-Epidemiology, Pathophysiology, and Management: A Narrative Review.Pain and therapy · 2024Review
- Dermal TRPV1 innervations engage a macrophage- and fibroblast-containing pathway to activate hair growth in mice.Developmental cell · 2024Article
- Article
- Neuroimmunophysiology of the gastrointestinal tract.American journal of physiology. Gastrointestinal and liver physiology · 2024Review
- Neuroimmune Interactions in the Intestine.Annual review of immunology · 2024Review
- Paraventricular thalamus-insular cortex circuit mediates colorectal visceral pain induced by neonatal colonic inflammation in mice.CNS neuroscience & therapeutics · 2024Article
- Traditional Chinese medicine for functional gastrointestinal disorders and inflammatory bowel disease: narrative review of the evidence and potential mechanisms involving the brain-gut axis.Frontiers in pharmacology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsChronic abdominal pain is a common symptom of inflammatory bowel diseases (IBDs). Peripheral and central mechanisms contribute to the transition from acute to chronic pain during active disease and clinical remission. Lower mechanical threshold and hyperexcitability of visceral afferents induce gliosis in central pain circuits, leading to persistent visceral hypersensitivity (VHS). In the spinal cord, microglia, the immune sentinels of the central nervous system, undergo activation in multiple models of VHS. Here, we investigated the mechanisms of microglia activation to identify centrally acting analgesics for chronic IBD pain.
methodsUsing Designer Receptors Exclusively Activated by Designer Drugs (DREADD) expressed in transient receptor potential vanilloid member 1-expressing visceral neurons that sense colonic inflammation, we tested whether neuronal activity was indispensable to control microglia activation and VHS. We then investigated the neuron-microglia signaling system involved in visceral pain chronification.
resultsWe found that chemogenetic inhibition of transient receptor potential vanilloid member 1
conclusionsOverall, these data provide novel insights into the central mechanisms of chronic visceral pain and suggest that targeting microglial P2RY12 signaling could be harnessed to relieve pain in patients with IBD who are in remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.